For too many people, chemo- and radiotherapy mean oral mucositis. So, before you start cancer therapy here’s what you need to know:
Oral mucositis is a side effect of cancer therapy and is characterised by a red, swollen and ulcerated mouth and tongue• The hallmark of oral mucositis is pain. The pain can become so severe that it is
• There are 4 stages of oral mucositis. Stage 1 and 2 are mild and characterised by
soreness and the beginning of ulceration. During stage 3 and 4, oral mucositis is more severe. At stage 3, sufferers cannot tolerate solid food and so switch to a liquid only diet. Eating is not possible at stage 4 so people may need further help getting enough nutrients1
• Many people develop mild oral mucositis as a result of cancer therapy, but stages
• Oral mucositis is called stomatitis by some doctors and nurses
Chemo- and radiotherapy• Chemo- and radiotherapy work by preventing the growth of new cancer
cells by killing rapidly dividing cancer cells that are already there
• Healthy mouth cells quickly divide and replace surface cells in the mouth with
new cells. However, cancer therapy also kills these dividing mouth cells meaning the surface cells cannot be replaced, causing ulcers to form
• The combination of chemo- and radiotherapy increases the risk of developing
severe oral mucositis.2 The symptoms of oral mucositis also tend to get worse the longer radiotherapy treatment lasts3
• Glands that produce saliva (spit) are also damaged so the mouth becomes dry
and more likely to be injured by hard food
For any pharmacovigilance or medical information requests about Caphosol®, please contact us at [email protected]
• There are many types of chemotherapy that are known to cause oral mucositis.
Some of these therapies are listed below:2
— 5-fluorouracil — methotrexate — doxorubicin — etoposide — melphalan — cytosine arabinoside — cyclophosphamide• All radiotherapy that passes in and near the mouth is very likely to cause
Most people receiving chemo- or radiotherapy are at risk. However, almost everyone receiving head and neck radiotherapy or a Hematopoietic Stem Cell Transplant (HSCT) (sometimes called a Bone Marrow Transplant [BMT]) will get oral mucositis• The likelihood of developing oral mucositis varies depending on the situation,
lifestyle and medical history of the person
Those at particular risk are: — young people and the elderly — those with previous oral health problems or oral mucositis — people who have poor oral hygiene during treatment — smokers — people who drink alcohol — diabetic patients — those receiving certain types of chemotherapy (see above)
• Typically people start noticing symptoms 5 to 8 days after starting chemotherapy.
The symptoms can last between 7 to 14 days before healing begins
• With each cycle of chemotherapy the risk of developing oral mucositis increases
and the severity of the condition often worsens3
• In some patients oral mucositis may last longer
With radiotherapy:• Oral mucositis develops later with radiotherapy (at 2 weeks) and healing
doesn’t begin until the end of therapy. Therefore, the symptoms can continue for up to 8 weeks
For any pharmacovigilance or medical information requests about Caphosol®, please contact us at [email protected]
For any pharmacovigilance or medical information requests about Caphosol®, please contact us at [email protected]
• Pain can make it very difficult to eat and drink, at a time when people with cancer
need the physical strength to cope with aggressive cancer therapies
Infection• The sores and ulcers that line a mouth are at serious risk of infection. If they do
get infected, the infection may be able to move into the blood. This is called a blood infection or septicaemia
• People receiving a Hematopietic Stem Cel Transplant (HSCT) are more likely to get
septicaemia, as treatment means their bodies are less able to fight off infection
Loss of taste• If the tongue is exposed during radiotherapy, the taste buds on the tongue’s
surface may become damaged. Some patients may even experience a complete loss of taste
• The taste buds will usually begin working normally again within 4 months of
finishing treatment, although the long-term effect is different from person-to-person and in some cases the taste buds may never fully recover
Treatment outcome• Many people develop oral mucositis so severely, that it affects the dose of
chemotherapy their body can cope with. This could ultimately influence the success of the cancer treatment
Other• People with oral mucositis can sometimes feel ashamed of their condition
and so they spend less and less time with their family, children and friends. This, coupled with the inability to eat and talk, can lead to social isolation and psychological distress
• In head and neck cancer patients, thick and sticky mucus often builds up inside
the mouth and throat. The use of a suction pump is sometimes required to dislodge this stringy saliva
• The use of a feeding tube may be necessary to ensure the person receives
enough food to cope with their therapy. The tube will be inserted through the nose if feeding is only needed for a short time, but it can be inserted directly into the stomach if longer term feeding is necessary
For information on how to treat and prevent oral mucositis speak to your doctor or nurse and read the other resource factsheets available at www.caphosol.com
References:
1. World Health Organisation. Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organisation,1979. 2. Treister N, Sook–Bin W.
Chemotherapy–Induced Oral Mucositis, 2008. Available at http://emedicine.medscape.com/article/1079570-overview. Last accessed January 2010. 3. Sonis ST. J Support Oncol 2004;2:3—8. 4. Pico J-L et al. The Oncologist 1998;3(6):446—451.
For any pharmacovigilance or medical information requests about Caphosol®, please contact us at [email protected] Date of preparation: April 2011
up-to-date, evidence-based treatment protocols Hazelden’s response to opioid dependence We at Hazelden will support you every step of the way. Our COR-12 programming offers you the best opportunity for lifelong recovery. Marvin D. Seppala, MD Chief Medical Officer Hazelden Foundation hazelden.org/cor12 800-257-7800 We invite you to call us with questions. We are av
SCL 104 – Medical Surgical Nursing I Spring 2007 Session II Clinical Professor: L. Rickets LAGUARDIA COMMUNITY COLLEGE CITY UNIVERSITY OF NEW YORK DEPARTMENT OF NATURAL & APPLIED SCIENCE PRACTICAL NURSING PROGRAM NURSING CARE CASE STUDY I. CLIENT-STUDENT INFORMATION Client information Student Practical Nurse II. INTRODUCTION I was randomly assigned